Insider Selling: DexCom (NASDAQ:DXCM) Insider Sells $2,042,017.92 in Stock

DexCom, Inc. (NASDAQ:DXCM) insider Kevin Sayer sold 26,756 shares of DexCom stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $76.32, for a total value of $2,042,017.92. Following the sale, the insider directly owned 328,970 shares of the company’s stock, valued at $25,106,990.40. This trade represents a 7.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

DexCom Trading Down 0.8%

DXCM opened at $74.54 on Friday. DexCom, Inc. has a one year low of $54.11 and a one year high of $87.00. The company has a market cap of $28.76 billion, a P/E ratio of 31.85, a PEG ratio of 1.24 and a beta of 1.45. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.64 and a current ratio of 1.95. The business’s 50-day simple moving average is $72.91 and its 200-day simple moving average is $69.10.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.61 by $0.09. The firm had revenue of $1.31 billion during the quarter, compared to analysts’ expectations of $1.29 billion. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The firm’s revenue was up 13.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.48 earnings per share. As a group, equities research analysts expect that DexCom, Inc. will post 2.57 EPS for the current fiscal year.

Hedge Funds Weigh In On DexCom

Several hedge funds have recently added to or reduced their stakes in DXCM. Banque Pictet & Cie SA increased its position in DexCom by 58.2% during the fourth quarter. Banque Pictet & Cie SA now owns 109,823 shares of the medical device company’s stock worth $7,289,000 after buying an additional 40,411 shares in the last quarter. Aberdeen Group plc boosted its stake in shares of DexCom by 9.0% during the fourth quarter. Aberdeen Group plc now owns 530,363 shares of the medical device company’s stock valued at $35,200,000 after acquiring an additional 43,990 shares during the last quarter. BOKF NA increased its position in DexCom by 175.7% during the 4th quarter. BOKF NA now owns 35,314 shares of the medical device company’s stock worth $2,344,000 after purchasing an additional 22,505 shares in the last quarter. Stephens Investment Management Group LLC raised its stake in DexCom by 21.1% in the 4th quarter. Stephens Investment Management Group LLC now owns 1,042,801 shares of the medical device company’s stock valued at $69,211,000 after purchasing an additional 181,701 shares during the last quarter. Finally, Eurizon Capital SGR S.p.A. purchased a new position in DexCom in the 4th quarter valued at about $3,231,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on DXCM shares. Weiss Ratings downgraded shares of DexCom from a “hold (c)” rating to a “hold (c-)” rating in a research report on Tuesday. Piper Sandler reissued an “overweight” rating and issued a $88.00 target price (up from $75.00) on shares of DexCom in a report on Monday, June 15th. Canaccord Genuity Group set a $82.00 price target on DexCom and gave the stock a “buy” rating in a research note on Monday, May 18th. Deutsche Bank Aktiengesellschaft assumed coverage on DexCom in a report on Tuesday, June 23rd. They issued a “buy” rating and a $86.00 price target on the stock. Finally, Barclays reaffirmed an “underweight” rating and issued a $64.00 price objective (down from $67.00) on shares of DexCom in a research note on Monday, May 18th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, DexCom has an average rating of “Moderate Buy” and a consensus price target of $84.71.

Key Headlines Impacting DexCom

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: DexCom reported second-quarter adjusted earnings of $0.70 per share, above the $0.61 analyst consensus and up from $0.48 a year earlier. Revenue increased 13.1% year over year to $1.31 billion, exceeding estimates of $1.29 billion. DexCom Q2 earnings and revenues top estimates
• Positive Sentiment: Management raised its fiscal 2026 revenue outlook to $5.2 billion-$5.3 billion, broadly above the roughly $5.2 billion consensus, citing sustained demand for its continuous glucose monitoring systems. DexCom raises annual revenue forecast on strong demand for glucose monitors
• Positive Sentiment: UBS reaffirmed a Buy rating and set a $96 price target, implying substantial upside from recent trading levels. Other analysts have also maintained favorable ratings, with a reported consensus target near $85.40. UBS reaffirms Buy rating
• Neutral Sentiment: The results point to continuing growth in CGM demand, but DexCom trades at a relatively high earnings multiple. Investors may focus on whether the upgraded outlook can justify the valuation following the stock’s rebound.
• Negative Sentiment: Insider Kevin Sayer sold 26,756 shares worth approximately $2.04 million under a pre-arranged Rule 10b5-1 plan. The scheduled transaction reduces his holdings by 7.52%, although it does not necessarily signal a change in the company’s outlook. DexCom insider share sale
• Negative Sentiment: A law firm solicited shareholders regarding potential fiduciary-duty claims involving DexCom insiders. The notice contains no established finding of wrongdoing, but such litigation-related headlines can add short-term uncertainty. DexCom shareholder litigation notice

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.